ATOPIC DERMATITIS
Clinical trials for ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new injection calm severe eczema when creams fall short?
Disease control Not yet recruitingThis study tests whether an investigational drug called tilrekimig, given as injections alongside medicated creams or ointments, can improve moderate-to-severe eczema (atopic dermatitis) in people aged 12 and older. Participants will be randomly assigned to receive either tilreki…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new biologic calm severe eczema?
Disease control Not yet recruitingThis clinical trial is testing whether the drug nemolizumab can help treat moderate-to-severe atopic dermatitis (a common type of eczema) in Chinese patients aged 12 and older. Participants will receive either nemolizumab or a placebo (a look-alike with no active drug) every four…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new injection match an existing eczema treatment?
Disease control Not yet recruitingThis trial is testing whether an experimental biologic called IBI3027 works as well as the approved drug dupilumab for people with moderate-to-severe atopic dermatitis (eczema). About 520 adults will be randomly assigned to receive either IBI3027 or dupilumab as a subcutaneous in…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a targeted antibody calm severe eczema?
Disease control Not yet recruitingThis first-in-human trial evaluates BYN-001, an antibody designed to block IL-25, a protein linked to atopic dermatitis (eczema). The study first tests the drug in healthy volunteers to assess safety and how it moves through the body, then in people with moderate to severe eczema…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Bionyra Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a pill outperform biologics for severe eczema?
Disease control Not yet recruitingThis study looks at how well upadacitinib, a daily pill, works compared to biologic injections for people with moderate-to-severe atopic dermatitis (eczema). The goal is to see if more patients can reach a state of minimal disease activity, meaning nearly clear skin and little to…
Matched conditions: ATOPIC DERMATITIS
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a common antibiotic boost eczema treatment?
Disease control Not yet recruitingThis trial investigates whether adding the antibiotic azithromycin to standard topical creams (betamethasone or tacrolimus) improves eczema symptoms in children aged 3 to 12 with mild to moderate atopic dermatitis. Researchers will measure changes in the Eczema Area and Severity …
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Friendly bacteria cream could soothe childhood eczema
Disease control Not yet recruitingThis study tests whether a probiotic ointment (containing live, friendly bacteria) can improve eczema in children aged 6 months to 15 years. The ointment is compared to a basic lotion over 28 days. Researchers measure skin redness, itching, and skin barrier function to see if the…
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: BioGaia AB • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a simpler eczema routine boost treatment success?
Disease control Not yet recruitingThis study explores whether giving people with mild-to-moderate eczema a straightforward treatment plan using only Opzelura cream helps them stick to their medication routine. Participants apply the cream twice daily until their skin clears, then as needed. Some participants also…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Tailored diet plans during pregnancy show promise in cutting preterm birth and diabetes risk
Disease control Not yet recruitingThe ROOT study is testing a personalized nutrition program for pregnant women. Participants receive standard prenatal care plus customized diet and lifestyle plans based on their genes and nutrient levels. The goal is to see if this approach can lower the chances of preterm birth…
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: GrowBaby Life Project • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Eczema cream showdown: which Non-Steroid treatment works best for kids?
Disease control Not yet recruitingThis study compares two prescription creams, tacrolimus and crisaborole, for treating mild to moderate eczema in children and teens aged 2 to 20. Both creams are steroid-free and aim to control inflammation without the side effects of long-term steroid use. Over 8 weeks, 72 parti…
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: Foundation University Islamabad • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New shot could soothe tough eczema for teens and adults
Disease control Not yet recruitingThis phase 3 study tests an injectable drug called MG-K10 for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. About 498 participants will receive either MG-K10 or a placebo to see if it safely reduces skin redness, itc…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Shanghai Mabgeek Biotech.Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Eczema breakthrough: bacteria removal may reduce skin flares
Disease control Not yet recruitingThis study tests whether clearing Staphylococcus aureus bacteria from the skin can reduce eczema severity in people with atopic dermatitis. Researchers will enroll 100 participants aged 6 and older with moderate-to-severe disease. The goal is to see if decolonization improves ski…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New study tests safer eczema treatment for pakistani patients
Disease control Not yet recruitingThis study compares two steroid-free ointments—crisaborole and tacrolimus—for treating mild-to-moderate eczema in 148 Pakistani patients aged 2 and older. Researchers will measure skin improvement and side effects over 8 weeks to see which works better and is safer. The goal is t…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Hayat Abad Medical Complex, Peshawar • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New shot could tame tough eczema Flare-Ups
Disease control Not yet recruitingThis phase 3 trial tests an injection called ADSTEM for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to standard treatments. About 286 people aged 19 to 70 will receive either the study drug or a placebo. The main goal is to see if the inje…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: EHL Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New eczema cream could be safer option for kids
Disease control Not yet recruitingThis study tests whether crisaborole 2% ointment works better than tacrolimus 0.1% ointment for children aged 2-18 with mild to moderate eczema. 66 children will apply one of the creams twice daily for 28 days. The main goal is to see how many achieve clear or almost clear skin b…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Shalamar Institute of Health Sciences • Aim: Disease control
Last updated Jun 26, 2026 14:28 UTC
-
Don't wash that baby! study tests if keeping vernix on prevents eczema
Prevention Not yet recruitingThis study tests whether leaving the white, creamy coating (vernix caseosa) on a newborn's skin for at least 24 hours after birth can prevent eczema (atopic dermatitis) during the first year of life. Over 1,300 mother-infant pairs in Chile will be randomly assigned to either keep…
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: Pontificia Universidad Catolica de Chile • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Salt shaker showdown: could less sodium mean less eczema itch?
Symptom relief Not yet recruitingThis study looks at whether lowering salt in your diet can make eczema less severe. Forty adults with eczema will eat a low-salt diet for 24 weeks. For 5 weeks they'll take salt pills, and for another 5 weeks they'll take placebo pills, to see the real effect of sodium. Researche…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Iron pills may ease eczema in teens, new study hopes to prove
Symptom relief Not yet recruitingThis study tests whether adding oral iron supplements to standard eczema treatment can reduce skin symptoms and improve quality of life in adolescents aged 12 to 16 with mild to moderate atopic dermatitis. Researchers will also check if iron levels in the blood affect how well th…
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New eczema drug HXN5003 enters first human safety trial
Symptom relief Not yet recruitingThis early-stage study tests a new drug called HXN5003 in 28 healthy adults to see if it is safe and how the body processes it. The drug is being developed for atopic dermatitis (eczema). Participants receive either the drug or a placebo, and researchers monitor for side effects …
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New eczema drug IBI3033 enters first human tests
Symptom relief Not yet recruitingThis early-stage trial is testing an experimental drug called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants will receive either IBI3033 or a placebo injection over…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Could a seawater balm soothe eczema as well as the gold standard?
Symptom relief Not yet recruitingThis study compares a new emollient balm made from seawater (Relipid+) to a leading balm (Lipikar) for mild to moderate eczema in people aged 6 months to 70 years. The goal is to see if the new balm works just as well at reducing symptoms and improving skin health. Researchers wi…
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: University Hospital, Caen • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could a simple cream boost eczema relief?
Symptom relief Not yet recruitingThis study tests whether adding URGO FilmoCream Eczema to standard steroid cream works better than steroid cream alone for treating atopic dermatitis. Researchers will compare two similar eczema lesions on each of 44 adults—one treated with steroids only, the other with steroids …
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: CEN Biotech • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Skin disease evolution under the microscope: a 17-Year look at what drives severity
Knowledge-focused Not yet recruitingThis study follows 5,000 people with common inflammatory skin conditions—like eczema, psoriasis, and hidradenitis suppurativa—over up to 17 years to see how their disease severity changes. Researchers will collect medical history, treatments, and symptom scores to identify factor…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New oral drug for eczema takes first step in human safety trial
Knowledge-focused Not yet recruitingThis early-stage study tests the safety and tolerability of an experimental oral drug called HRS-8797 in healthy volunteers aged 18 to 55. Researchers will also measure how the drug behaves in the body and whether food affects its absorption. The goal is to gather essential safet…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Grain-of-Rice device could end guesswork in skin treatment
Knowledge-focused Not yet recruitingThis study tests a tiny microdevice, about the size of a grain of rice, that holds up to 20 different FDA-approved skin medications. Placed directly on the skin, it releases very small amounts of each drug to see how the skin reacts. The goal is to find out if this device can saf…
Matched conditions: ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Could a sticker on your skin reveal hidden clues about acne and eczema?
Knowledge-focused Not yet recruitingThis study is testing a new, non-invasive way to collect and analyze skin oil (sebum) using a simple adhesive patch called Sebutape. Researchers will recruit 200 people, including healthy volunteers and patients with acne, eczema, psoriasis, or seborrheic dermatitis. The goal is …
Matched conditions: ATOPIC DERMATITIS
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Costa rica launches registry to track eczema treatments in daily practice
Knowledge-focused Not yet recruitingThis study will follow 50 Costa Rican patients with moderate-to-severe atopic dermatitis (eczema) who are receiving advanced treatments like dupilumab or JAK inhibitors as part of their regular care. Researchers will collect information on patient characteristics, treatment patte…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Caja Costarricense de Seguro Social • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Eye scans could reveal hidden skin disease risk
Knowledge-focused Not yet recruitingThis study will take high-resolution photos of the eyes of 950 people with psoriasis, eczema, or hives, plus healthy volunteers. Using artificial intelligence, researchers aim to find eye patterns linked to these skin conditions. The goal is to create a noninvasive tool for earli…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Shanghai Yueyang Integrated Medicine Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Eczema's hidden toll: new study to measure caregiver burden
Knowledge-focused Not yet recruitingThis study looks at how caring for a child with mild to moderate eczema (atopic dermatitis) affects caregivers' work and family life. About 100 Canadian caregivers will answer questionnaires about missed work, reduced productivity, and family impact. The goal is to better underst…
Matched conditions: ATOPIC DERMATITIS
Sponsor: PeriPharm • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Italian skin disease registry aims to map treatment journeys for 20,000 patients
Knowledge-focused Not yet recruitingThis study will collect existing medical records from about 20,000 people aged 12 and older in Italy who have one of five inflammatory skin conditions: psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa. Researchers want to describe who gets thes…
Matched conditions: ATOPIC DERMATITIS
Sponsor: Fondazione ISIDE • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC